Related Experiment Video
Updated: May 24, 2026
Reduced Complications after Arterial Reconnection in a Rat Model of Orthotopic Liver Transplantation
Published on: November 7, 2020
Natural history, risk factors and management of hepatitis C after liver transplantation
1Nebraska Medical Center, Division of Gastroenterology and Hepatology, Omaha, Nebraska 68198-3285, USA. smukherj@unmc.edu
Insights
Recurrent Hepatitis C virus (HCV) after liver transplant often leads to cirrhosis. Current interferon-based therapies show limited success and significant toxicity in transplant recipients, questioning their use for HCV genotype 1.
Area of Science:
- Hepatology
- Transplantation Immunology
- Virology
Background:
- Recurrent Hepatitis C virus (HCV) infection is common after liver transplantation in patients with pre-existing viremia.
- It frequently leads to graft cirrhosis and is a growing indication for retransplantation.
- Standard interferon-based therapies effective in non-transplant patients often fail in liver transplant recipients due to intolerance and limited efficacy.
Purpose of the Study:
- To evaluate the efficacy and safety of current treatment options for recurrent HCV genotype 1 in liver transplant recipients.
- To address the controversy surrounding the use of interferon-based therapies in this patient population.
- To explore the challenges posed by new antiviral agents in the context of liver transplantation.
Main Methods:
- Review of existing literature on HCV treatment in liver transplant recipients.
- Analysis of outcomes with pegylated interferon and ribavirin therapy.
- Examination of contraindications and toxicity profiles of new protease inhibitors.
Main Results:
- Viral eradication rates are low with standard therapies in transplant patients.
- High rates of drug intolerance and severe side effects are reported.
- New protease inhibitors are contraindicated due to severe drug toxicity in this population.
Conclusions:
- The efficacy of interferon-based therapies for recurrent HCV genotype 1 in liver transplant recipients remains questionable due to poor outcomes and toxicity.
- Effective and safe treatment options for post-transplant HCV are urgently needed.
- Current treatment guidelines require careful consideration for liver transplant patients with recurrent HCV genotype 1.
Abstract:
Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation. Despite encouraging results with pegylated interferon and ribavirin therapy in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful largely due to drug intolerance. The lack of effective therapies, severe side effects and reports of hepatic decompensation despite HCV eradication raises the question of whether recurrent HCV genotype 1 should be treated with interferon-based therapies. Although protease inhibitors were recently approved for the treatment of genotype 1 HCV patients in combination with pegylated interferon and ribavirin, these new agents are contraindicated in liver transplant patients due to severe drug toxicity.
Related Concept Videos
01:25Hepatitis
01:16Kidney Transplant III: Nursing Management
01:28Viral Hepatitis I: Introduction
01:28Kidney Transplant I: Introduction
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:24Cirrhosis II: Pathophysiology